Now available: The AmoyDx® Myeloid Blood Cancer Panel
The AmoyDx® Myeloid Blood Cancer Panel enables a comprehensive molecular genetic analysis for the qualitative detection of SNVs, InDels and fusions in 55 genes associated with myeloid leukemia on DNA and RNA.
The AmoyDx® Myeloid Blood Cancer Panel is a Next-Generation Sequencing-based assay for the detection of mutations (SNVs), insertions and deletions (InDels) as well as fusions in 55 genes on DNA and RNA from bone marrow aspirates. In total, 252 different gene fusions can be detected using this assay.
The focus of this assay is on the tumor entities AML and CML, but may be further suited to characterize other hematologic malignancies. The analysis of the sequence data can be performed locally using the AmoyDx® NGS Data Analysis System (ANDAS).
Please find a detailed description of the AmoyDx® Myeloid Blood Cancer Panel here
This product is for research use only (RUO)
